Impact of Lipodystrophy on the Inflammatory State of Non-diabetic Dunnigan Reunion Island Subjects (LIPOKINES)

Centre Hospitalier Universitaire de la Réunion

Status: Enrolling

Conditions: Dunnigan Syndrome; Lipodystrophy

Treatments: Biological: Bood and urine sampling

Study type: Interventional

Funder types: Other

Identifiers

NCT06107439

2021/CHU/12

Details and patient eligibility

About

Few data and small numbers affect the inflammatory profile of Dunnigan patients. The levels of certain pro-inflammatory biomarkers would be found higher in these subjects compared to control individuals. However, in these studies, several confounding factors were not taken into account such as smoking, an underlying chronic inflammatory disease such as diabetes and could limit the interpretation of the results. There is no other observation of the anti-inflammatory status of these patients.

Enrollment: 80 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Adult subject (>18 years old) affected by partial Dunnigan lipodystrophy in the homozygous or heterozygous state (genetic search for the positive mutation carried out before inclusion in the study).
• Person affiliated to or beneficiary of a social security scheme.
• Free, informed and written consent signed by the participant and the investigator.

Exclusion criteria

• • Minor
• Persons placed under judicial protection, person participating in another research including a period of exclusion still in progress, severely impaired physical and/or psychological health, which, according to the investigator, may affect the participant's compliance with the study
• Previous known diabetes
• Pregnant woman
• Woman who gave birth less than 6 months ago
• Breastfeeding in progress
• Participation in other research that may have an impact on the evaluation of the main judgment criteria
• Hemoglobin b level < 7 mg/dl or < 9-10 mg/dl for patients with cardiovascular or respiratory pathology.
• Proven inflammatory pathologies
• Anti-inflammatory treatment: taking corticosteroids in the last 3 months.
• Active smoking

Trial design

Primary purpose: Health Services Research

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

80 participants in 1 patient group

sampling and clinical data collection

Other group

Description:

Participant blood and urine are sampled for inflammatory signal analysis

Treatment:

Biological: Bood and urine sampling